NYSE:SOLVMedical Equipment
Solventum (SOLV): Assessing Valuation After New Clinical Guidance Expands Prevena Therapy’s Surgical Use
Solventum (SOLV) just picked up a meaningful endorsement, with new international clinical guidance expanding how its Prevena closed incision negative pressure therapy can be used across surgeries that prioritize patient safety.
See our latest analysis for Solventum.
These endorsements and the recent Acera Surgical deal have arrived against a constructive backdrop, with Solventum’s 90 day share price return of 9.44 percent and year to date share price return of 22.37 percent hinting that...